Association Between an Acute, Drug-Induced Decrease in High-Density Lipoprotein Cholesterol Levels and Risk of...

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Epidemiology

Background:

• Limited literature exists on the long-term cardiovascular (CV) risk associated with acute, drug-induced decreases in high-density lipoprotein cholesterol (HDL-C).
• Understanding this association is crucial for managing patients on lipid-lowering therapies.

Purpose of the Study:

• To investigate the potential association between a short-term, drug-induced decrease in HDL-C and long-term CV risk.
• To analyze the impact of acute HDL-C level changes on major adverse cardiac events (MACE).

Main Methods:

• A retrospective cohort study utilized the Clinical Practice Research Datalink (CPRD) from 2006 to 2014.
• Patients initiating short-term statin therapy were identified, with HDL-C measured before and after initiation.
• Follow-up for up to 5 years assessed major adverse cardiac events (MACE), comparing patients with decreased HDL-C to those with constant HDL-C levels.

Main Results:

• 17,543 patients were analyzed, with 6,454 in the HDL-C decrease group and 11,089 in the HDL-C constant group.
• The 5-year cumulative incidence of MACE was 5.91% in the HDL-C constant group.
• Patients with HDL-C decrease showed a 1.23% higher risk of MACE (HR 1.20), primarily driven by increased risks of ischemic stroke and CV death.

Conclusions:

• A short-term, drug-induced decrease in HDL-C is associated with a moderately increased long-term risk of CV events.
• This finding suggests that acute changes in HDL-C levels may have significant long-term cardiovascular implications.